A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Batoprotafib (Primary) ; Opnurasib (Primary) ; Tislelizumab (Primary)
Indications Biliary cancer; Carcinoma; Colorectal cancer; Duodenal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms KontRASt-01
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

17 Dec 2024 Planned End Date changed from 5 Aug 2025 to 30 Apr 2026.
17 Dec 2024 Planned primary completion date changed from 4 Aug 2025 to 30 Apr 2026.
06 Dec 2024 Planned End Date changed from 20 Mar 2026 to 5 Aug 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com